FDA Approves Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

DUBLIN, June 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news

Related Links:

an Fisher Although chimeric antigen receptor (CAR) T cells have shown impressive clinical success against haematological malignancies such as B cell lymphoma and acute lymphoblastic leukaemia, their efficacy against non-haematological solid malignancies has been largely disappointing. Solid tumours pose many additional challenges for CAR T cells that have severely blunted their potency, including homing to the sites of disease, survival and persistence within the adverse conditions of the tumour microenvironment, and above all, the highly immunosuppressive nature of the tumour milieu. Gene engineering approaches for ge...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially B-cell precursor acute lymphoblastic leukaemia (BCP-ALL), has been spectacular. However, currently, there are scientific, clinical and logistical challenges for use of CAR T-cells in BCP-ALL and other paediatric malignancies, particularly in acute myeloid leukaemia (AML), lymphomas and solid tumours.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
CONCLUSION: The outcomes of patients treated with haplo-SCT appear comparable with those of the SCTs using other sources. The higher probability of developing GVHD supports the need for a novel method to harness T-cell alloreactivity.PMID:34802994 | DOI:10.1016/j.clml.2021.09.024
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research
Curr Res Transl Med. 2021 Nov 8;70(1):103320. doi: 10.1016/j.retram.2021.103320. Online ahead of print.ABSTRACTThe advent of chimeric antigen receptor (CAR)-T cell therapy has been hailed as a major breakthrough in the treatment of B cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). While multiple promising CAR-T cell clinical trials continue to receive approval from the FDA and the Chinese Clinical Trial Register (ChiCTR), many hematologic malignancies patients nonetheless experience disease relapse following treatment as a consequence of genetic mutations, antigen escape, lineage switch...
Source: Cell Research - Category: Cytology Authors: Source Type: research
Condition:   B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoma Intervention:   Biological: anti-CD19 UCAR-T injection Sponsors:   920th Hospital of Joint Logistics Support Force of People's Liberation Army of China;   Gracell Biotechnology Shanghai Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Chimeric antigen receptor T-cell (CAR-T) therapy has been successful in creating extraordinary clinical outcomes in the treatment of hematologic malignancies including relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). With several FDA approvals, CAR-T therapy is recognized as an alternative treatment option for particular patients with certain conditions of B-ALL, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, or multiple myeloma. However, CAR-T therapy for B-ALL can be surrounded by challenges such as various adverse events including the life-threatening cytokine release ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
: Most likely due to the availability of potential stem cell sources, there appears to be a growing usage of haploidentical (haplo) donors for cases of acute lymphoblastic leukemia involving high-risk features or relapse.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
In this study, we investigated whether the inclusion of the inducible caspase 9 (iC9) suicide gene in the CAR construct design could be an effective safety switch to control malignant CAR+ B cells, ultimately counteracting this serious adverse event. iC9 is a suicide gene able to be activated through binding with an otherwise inert small biomolecule, known as AP1903. The exposure of iC9.CAR.CD19-DAUDI lymphoma and iC9.CAR.CD19-NALM-6 leukemia cells in vitro to 20 nM of AP1903 resulted into the prompt elimination of CAR+ B-leukemia/lymphoma cell lines. The results obtained in the animal model corroborate in vitro data, sinc...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Expert Rev Anticancer Ther. 2021 Oct 12. doi: 10.1080/14737140.2021.1991316. Online ahead of print.ABSTRACTINTRODUCTION: Doxorubicin (DOX) is a Streptomyces peucetius-derived antibiotic and is a member of the anthracyline family. DOX exerts strong anticancer activity and has been in the practice of cancer treatment since the 1960s. DOX is commonly used to treat different cancers, including bone sarcomas, soft tissue (tendons and muscles), bladder, ovary, stomach, thyroid, breast, acute lymphoblastic leukemia, Hodgkin lymphoma, lung cancer, and myeloblastic leukemia. Although, the cumulative doses of DOX above 550mg/m2 caus...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Authors: Source Type: research
Long-term remission is elusive after CD19 chimeric antigen receptor (CAR) T cell therapy for refractory/relapsed CD19+ B cell acute lymphoblastic leukemia (B-ALL) [1 –6]. A high percentage of subjects achieve initial complete remission (CR), but one-half of subjects experience disease recurrence within 6 to 18 months after CAR T cell infusion [1,4,7].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Drugs & Pharmacology | Food and Drug Administration (FDA) | Leukemia | Lymphoma